Saltar al contenido
Merck

F0005000

Famotidine

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Famotidine, N′-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula empírica (notación de Hill):
C8H15N7O2S3
Número CAS:
76824-35-6
Peso molecular:
337.45
NACRES:
NA.24
PubChem Substance ID:
329799617
UNSPSC Code:
41116107
MDL number:
MFCD00079297

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

InChI

1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

SMILES string

N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1

InChI key

XUFQPHANEAPEMJ-UHFFFAOYSA-N

biological source

synthetic

grade

pharmaceutical primary standard

agency

EP Reference Standard

API family

famotidine

form

solid

packaging

pkg of 110 mg

manufacturer/tradename

EDQM

storage condition

protect from light

application(s)

pharmaceutical (small molecule)

format

neat

shipped in

ambient

storage temp.

2-8°C

Gene Information

human ... HRH2(3274)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

Famotidine is a hydrophilic, cationic, histamine H2 receptor antagonist drug that effectively inhibits gastric acid secretion in humans.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

H2 histamine receptor antagonist; anti-ulcer agent

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Famotidine
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 29(1-2), 2609-2610 (2017)
Determination of cimetidine, famotidine, and ranitidine hydrochloride in the presence of their sulfoxide derivatives in pure and dosage forms by high-performance thin-layer chromatography and scanning densitometry
Kelani KM, et al.
Journal of AOAC (Association of Official Analytical Chemists) International, 85(5), 1015-1020 (2002)
K Yoshimoto et al.
Clinical pharmacology and therapeutics, 55(6), 693-700 (1994-06-01)
Central nervous system toxicity of H2-receptor antagonists has rarely been confirmed by the respective elevated cerebrospinal fluid drug concentrations. We observed two hemodialyzed neurosurgical patients in whom mental deterioration and convulsions developed after intravenous famotidine therapy (10 and 40 mg/day).
H D Langtry et al.
Drugs, 38(4), 551-590 (1989-10-01)
Famotidine is a highly selective histamine H2-receptor antagonist. In healthy volunteers and patients with acid hypersecretory disease it is approximately 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and 8 times more potent than ranitidine
Occupational allergic contact dermatitis from intermediate products in famotidine synthesis.
D Guimaraens et al.
Contact dermatitis, 31(4), 259-260 (1994-10-01)
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico